Galapagos split stutters
The group’s point-of-care Car-T push looks to have stalled.
Another Roche TIGIT disappointment
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
Vor looks to answer the Car-T question
Can the company add a Car-T string to its stem cell transplant bow?
Make or break time for Caribou
The company’s matching strategy for CB-010 will soon be put to the test.
How to be different in in vivo Car-T
After Astra's EsoBiotec takeover the battle for uniqueness begins.
